When was Biotest Pharmaceuticals founded?

Biotest Pharmaceuticals was founded in 2007.

Where is Biotest Pharmaceuticals located?

Biotest Pharmaceuticals is headquartered in Boca Raton, United States.

Who is the current CEO of Biotest Pharmaceuticals?

Ileana Carlisle of Biotest Pharmaceuticals.

Where does Biotest Pharmaceuticals rank among its competitors?

Biotest Pharmaceuticals ranks 1840th amongst 3501 active competitors, of which 1147 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Biotest Pharmaceuticals?

Biotest Pharmaceuticals' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Biotest Pharmaceuticals - 2026 Company Profile, Team & Competitors

Company Details

Biotest Pharmaceuticals is a subsidiary of Biotest AG. It researches and manufactures biotherapeutic products with a specialization in immunology and liver transplant therapy. The company is also involved in the collection of source plasma and engages in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and development of therapies to prevent re-infection of transplanted livers. The lead product of the company is Hepatitis C Immune Globulin (HCIG), a polyclonal antibody, which has a wide range of clones targeting Hepatitis C, it has been designed to prevent reoccurrence of HCV in HCV-positive liver transplant patients.

Website: biotestpharma.com
Social
Email ID: *****@biotestpharma.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2007

Location

Boca Raton, United States

Stage

Acquired

Ranked

1840^th among 3501 active competitors

Similar Companies

BeiGene & 735 more

Exit Details

Acquired by Grifols (Aug 01, 2018)

View Biotest Pharmaceuticals' full profile

Biotest Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Biotest Pharmaceuticals Corporation CIN: 261251037 , United States, Active	Jun 15, 2017	-	685 (As on Dec 31, 2024)	-

Biotest Pharmaceuticals got acquired by Grifols on Aug 01, 2018 at an acquisition amount of $*****.

Click here to take a look at Biotest Pharmaceuticals's acquisition in detail

Biotest Pharmaceuticals has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biotest Pharmaceuticals include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Biotest Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
1840th	Biotest Pharmaceuticals 2007, Boca Raton (United States), Acquired	Manufactures bio therapeutics in immunology and liver	-	-	30/100